Amneal Pharmaceuticals, Inc. $AMRX Stock Holdings Lessened by Tucker Asset Management LLC

Tucker Asset Management LLC lessened its stake in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) by 49.5% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 511,064 shares of the company’s stock after selling 500,000 shares during the quarter. Amneal Pharmaceuticals makes up 2.5% of Tucker Asset Management LLC’s holdings, making the stock its 6th biggest position. Tucker Asset Management LLC’s holdings in Amneal Pharmaceuticals were worth $10,293,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Allspring Global Investments Holdings LLC grew its stake in shares of Amneal Pharmaceuticals by 72.2% in the first quarter. Allspring Global Investments Holdings LLC now owns 2,549,572 shares of the company’s stock valued at $32,405,000 after buying an additional 1,069,400 shares in the last quarter. Bank of New York Mellon Corp acquired a new position in Amneal Pharmaceuticals during the second quarter worth $17,573,000. Principal Financial Group Inc. raised its position in Amneal Pharmaceuticals by 527.9% during the first quarter. Principal Financial Group Inc. now owns 972,529 shares of the company’s stock worth $12,089,000 after acquiring an additional 817,652 shares in the last quarter. Congress Asset Management Co. raised its position in Amneal Pharmaceuticals by 94.7% during the third quarter. Congress Asset Management Co. now owns 1,524,355 shares of the company’s stock worth $30,701,000 after acquiring an additional 741,577 shares in the last quarter. Finally, Quartz Partners LLC bought a new stake in Amneal Pharmaceuticals during the first quarter worth $5,559,000. 31.82% of the stock is owned by institutional investors.

Amneal Pharmaceuticals Stock Performance

Shares of NASDAQ AMRX opened at $20.44 on Tuesday. The company has a current ratio of 2.20, a quick ratio of 1.44 and a debt-to-equity ratio of 77.65. The company has a market capitalization of $6.53 billion, a P/E ratio of 24.58, a P/E/G ratio of 2.46 and a beta of 1.22. Amneal Pharmaceuticals, Inc. has a 12 month low of $10.68 and a 12 month high of $21.68. The stock has a 50 day moving average of $19.17 and a 200-day moving average of $15.78.

Analyst Ratings Changes

A number of research analysts have recently commented on the stock. Leerink Partners started coverage on shares of Amneal Pharmaceuticals in a research report on Wednesday, September 9th. They issued an “outperform” rating and a $23.00 price objective for the company. Oppenheimer initiated coverage on shares of Amneal Pharmaceuticals in a research note on Wednesday, September 23rd. They set an “outperform” rating and a $27.00 price objective on the stock. Barclays upped their target price on shares of Amneal Pharmaceuticals from $16.00 to $20.00 and gave the company an “overweight” rating in a report on Thursday, September 17th. UBS Group reiterated a “buy” rating on shares of Amneal Pharmaceuticals in a research note on Thursday, October 1st. Finally, Wall Street Zen upgraded Amneal Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Sunday, July 12th. Eight analysts have rated the stock with a Buy rating and one has given a Hold rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $22.86.

Insider Activity at Amneal Pharmaceuticals

In other Amneal Pharmaceuticals news, EVP Jason B. Daly sold 210,000 shares of Amneal Pharmaceuticals stock in a transaction on Wednesday, August 12th. The shares were sold at an average price of $17.40, for a total transaction of $3,654,000.00. Following the completion of the transaction, the executive vice president directly owned 35,171 shares of the company’s stock, valued at $611,975.40. The trade was a 85.65% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director John Kiely sold 50,000 shares of the company’s stock in a transaction on Thursday, August 13th. The shares were sold at an average price of $17.64, for a total transaction of $882,000.00. Following the completion of the transaction, the director owned 210,252 shares in the company, valued at approximately $3,708,845.28. This represents a 19.21% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders have sold 413,016 shares of company stock worth $7,216,567. Company insiders own 17.30% of the company’s stock.

Amneal Pharmaceuticals Profile

Amneal Pharmaceuticals, Inc is a specialty pharmaceutical company that develops, manufactures and commercializes a broad portfolio of generic and specialty medicines. Its products include oral, injectable and inhaled medications, as well as complex dosage forms and other products designed to address areas where manufacturing or formulation requirements can be more challenging.

The company’s generics business offers medicines across a range of therapeutic categories, including central nervous system, cardiovascular, gastrointestinal, anti-infective and other treatments.